Impact of hydroxychloroquine on atherosclerosis and vascular stiffness in the presence of chronic kidney disease

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Shukla, Ashutosh M ^a,b   Bose, Chhanda ^c,d   Karaduta, Oleg K ^c,d   Apostolov, Eugene O ^c,d   Kaushal, Gur P ^c,d   Fahmi, Tariq ^c,d   Segal, Mark S ^a,b   Shah, Sudhir V ^c,d  

^a North Florida/South Georgia VA Healthcare System   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; HYDROXYCHLOROQUINE; PLACEBO; BILIRUBIN; GLUCOSE BLOOD LEVEL; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ECHOGRAPHY; ELASTICITY; ENDOTHELIAL DYSFUNCTION; HISTOPATHOLOGY; INFLAMMATION; KIDNEY FUNCTION; KNOCKOUT MOUSE; LIPID DIET; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; SHAM PROCEDURE; SURGICAL TECHNIQUE; VASCULAR ENDOTHELIUM; ANIMAL; AORTA; BLOOD; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; POSTMORTEM CHANGE; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; AORTA; ATHEROSCLEROSIS; BILIRUBIN; BLOOD GLUCOSE; ELASTICITY; HYDROXYCHLOROQUINE; INFLAMMATION; MALE; MICE, INBRED C57BL; POSTMORTEM CHANGES; RENAL INSUFFICIENCY, CHRONIC; UREA; VASCULAR STIFFNESS;

EID: 84946896224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139226     Document Type: Article

References (45)

1. McCullough PA, Agrawal V, Danielewicz E, Abela GS. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(6):1585-698. doi: 10.2215/CJN.01930408 PMID: 18667741
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. PMID: 15385656
3. Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol. 2010 5(9):1595-601. doi: 10.2215/CJN.09301209 PMID: 20671217
4. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. doi:10. 1056/NEJMoa0907845 PMID: 19880844
5. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395-407. doi: 10.1056/NEJMoa0810177 PMID: 19332456
6. Wanner C, Krane V, Winfried M, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238-48. PMID: 16034009
7. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339(9):584-90. PMID: 9718377
8. Ivanovski O, Szumilak Dl, Nguyen-Khoa Tl, Nikolov IG, Joki N, Mothu N, et al. Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. J Urol. 2008; 179(4):1631-6. doi: 10.1016/j.juro.2007.11.042 PMID: 18295249
9. Group FT, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In-center hemodialysis six times per week versus three times per week. New Engl J Med. 2010; 363(24):2287-300. doi: 10.1056/ NEJMoa1001593 PMID: 21091062
10. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012; 367(26):2482-94. doi: 10.1056/NEJMoa1205624 PMID: 23121374
11. United States Renal Data System 2012 Annual Data Report: Atlas of chronic kidney disease and endstage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
12. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007 116(1):85-97. PMID: 17606856
13. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004; 291(4):451-9. PMID: 14747502
14. Sisó A, Ramos-Casals M, Bové A, Brito-Zerón P, Soria N, Muñoz S, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008; 17 (4):281-8. doi: 10.1177/0961203307086503 PMID: 18413408
15. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wózniacka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus. 2010; 19(6):683-8. doi: 10.1177/0961203309356455 PMID: 20064914
16. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006; 4(5):377-89. PMID: 17084711
17. Razani B, Feng C, Semenkovich CF. P53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res. 2010; 51(7):1738-46. doi: 10.1194/jlr.M003681 PMID: 20208057
18. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006; 45(6):703-10. doi: 10.1093/rheumatology/kei282
19. Picot S, Peyron F, Vuillez JP, Polack B, Ambroise-Thomas PC. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro. J Infect Dis. 1991; 164(4):830.
20. Gagnon RF, Ansari M. Development and progression of uremic changes in the mouse with surgically induced renal failure. Nephron. 1990; 54(1):70-6. PMID: 2296348
21. Apostolov EO, Ray D, Savenka AV, Shah SV, Basnakian AG. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol. 2010; 21(11):1852-7 doi: 10.1681/ASN.2010040365 PMID: 20947625
22. Ruiz-Irastorza G, Egurbide M, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006; 15(9):577-83. PMID: 17080912
23. Wikström J, Grönros J, Bergström G, Gan L-m. Functional and morphologic imaging of coronary atherosclerosis in living mice using high-resolution color Doppler echocardiography and ultrasound biomicroscopy. J Amer Coll Cardiol. 2005; 46(4):720-7. http://dx.doi.org/10.1016/j.jacc.2005.04.053.
24. Gan LM, Grönros J, Hägg U, Wikström J, Theodoropoulos C, Friberg P, et al. Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. Atherosclerosis. 2007; 190(2):313-20. doi: 10.1016/j.atherosclerosis.2006.03.035 PMID: 16677654
25. Goff DC Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2): S49-73. doi: 10.1161/01.cir.0000437741.48606.98 PMID: 24222018
26. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25-PA). doi: 10.1016/j.jacc.2013.11.002 PMID: 24239923
27. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease2013 2013-10-07 00:00:00. 2949-3003 p.
28. Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets. 2009; 8(5):369-82. PMID: 20025585
29. Davignon J, Ganz P. Role of Endothelial Dysfunction in Atherosclerosis. Circulation. 2004; 109(23 suppl 1):III-27-III-32. doi: 10.1161/01.CIR.0000131515.03336.f8
30. Ghigo D, Aldieri E, Todde R, Costamagna C, Garbarino G, Pescarmona G, et al. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest. 1998; 102 (3):596-605.
31. Tawakol A, Muller J. Through the looking glass: an angioscopic view of the effect of statin therapy on coronary artery plaques. J Am Coll Cardiol. 2003; 42(4):687-9. PMID: 12932602
32. Tawakol A, Castano AP, Anatelli F, Bashian G, Stern J, Zahra T, et al. Photosensitizer delivery to vulnerable atherosclerotic plaque: comparison of macrophage-targeted conjugate versus free chlorin(e6). J Biomed Opt. 2006; 11(2):021008. PMID: 16674183
33. Todorovic Z, Medic B, Basta-Jovanovic G, Radojevic Skodric S, Stojanovic R, Rovcanin B, et al. Acute pretreatment with chloroquine attenuates renal I/R injury in rats. PLoS One. 2014 9(3):e92673. doi:10. 1371/journal.pone.0092673 PMID: 24681567
34. Gómez-Guzmán M, Jiménez R, Romero M, Sánchez M, Zarzuelo MJ, Gómez-Morales M, et al. Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2014; 64(2):330-7. doi: 10.1161/HYPERTENSIONAHA. 114.03587 PMID: 24842914
35. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O. Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus. Basic Clin Pharmacol Toxicol. 2010; 107(6):919-24. doi: 10.1111/j.1742-7843.2010.00604.x PMID: 20560926
36. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001; 37(4):1075-82. PMID: 11304506
37. Borba EF, Bonfá E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001; 28(4):780-5. PMID: 11327250
38. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis. 2010; 69(1):20-8. doi: 10.1136/ard.2008.101766 PMID: 19103632
39. Lorber M, Aviram M, Linn S, Scharf Y, Brook JG. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol. 1985 24(3):250-5. PMID: 3860273
40. Martinet W, De Meyer GY. Autophagy in atherosclerosis. Curr Atheroscler Rep. 2008; 10(3):216-23. PMID: 18489849
41. Gustafsson ABGRA. Autophagy in ischemic heart disease. Circ Res. 2009; 104(2):150-8. doi:10. 1161/CIRCRESAHA.108.187427 PMID: 19179668
42. Mei Y, Thompson MD, Cohen RA, Tong X. Autophagy and oxidative stress in cardiovascular diseases. Biochim Biophys Acta. 2014:pii: S0925-4439(14)00133-1. doi: 10.1016/j.bbadis.2014.05.005 [Epub ahead of print]. PMID: 24834848
43. Lavandero S, Troncoso R, Rothermel BA, W. M, Sadoshima J, Hill JA. Cardiovascular autophagy: Concepts, controversies, and perspectives. Autophagy. 2013; 9(10):1455-66. doi: 10.4161/auto.25969 PMID: 23959233
44. Leung N, Shaikh A, Cosio FG, Griffin MD, Textor SC, Gloor JM, et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant. 2010; 10 (3):558-62. doi: 10.1111/j.1600-6143.2009.02959.x PMID: 20055804
45. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th edition. Philadelphia, PA: American College of Physicians; 2007. 272 p.